Clinical Trials · NCT04311411
A Study of Tirzepatide in Overweight and Very Overweight Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 114
- Start date
- Aug 2020
- Locations
- 3 sites, United States
- Primary endpoint
- Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3